Alembic Pharmaceuticals Limited

NSEI:APLLTD Stock Report

Market Cap: ₹170.8b

Alembic Pharmaceuticals Past Earnings Performance

Past criteria checks 4/6

Alembic Pharmaceuticals's earnings have been declining at an average annual rate of -12.6%, while the Pharmaceuticals industry saw earnings growing at 17% annually. Revenues have been growing at an average rate of 7.7% per year. Alembic Pharmaceuticals's return on equity is 12.8%, and it has net margins of 9.9%.

Key information

-12.6%

Earnings growth rate

-13.6%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate7.7%
Return on equity12.8%
Net Margin9.9%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly

Jun 03
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly

Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?

May 11
Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 08
Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Jan 21
Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Jan 05
Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly

Sep 27
Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Jun 09
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Apr 13
A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Feb 22
Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jan 04
Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now

Nov 05
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden

Aug 10
Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden

Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Jul 20
Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt

May 05
We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Jan 17
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Are Alembic Pharmaceuticals Limited (NSE:APLLTD) Investors Paying Above The Intrinsic Value?

Dec 17
Are Alembic Pharmaceuticals Limited (NSE:APLLTD) Investors Paying Above The Intrinsic Value?

These 4 Measures Indicate That Alembic Pharmaceuticals (NSE:APLLTD) Is Using Debt Reasonably Well

Sep 23
These 4 Measures Indicate That Alembic Pharmaceuticals (NSE:APLLTD) Is Using Debt Reasonably Well

Is There An Opportunity With Alembic Pharmaceuticals Limited's (NSE:APLLTD) 27% Undervaluation?

Sep 02
Is There An Opportunity With Alembic Pharmaceuticals Limited's (NSE:APLLTD) 27% Undervaluation?

Revenue & Expenses Breakdown

How Alembic Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:APLLTD Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2462,2866,15814,4630
31 Dec 2361,1815,90213,4840
30 Sep 2359,9665,31712,9040
30 Jun 2358,7665,28512,3320
31 Mar 2356,5263,42011,7550
31 Dec 2256,6192,11311,5400
30 Sep 2254,2462,66211,3540
30 Jun 2252,4193,15311,3350
31 Mar 2253,0585,20911,3820
31 Dec 2151,7047,60910,9510
30 Sep 2152,1318,77110,8480
30 Jun 2153,77810,41210,6780
31 Mar 2153,93111,46510,5140
31 Dec 2053,19611,52110,6390
30 Sep 2052,14410,93710,2830
30 Jun 2049,98210,0669,6990
31 Mar 2046,0588,2889,0940
31 Dec 1943,2597,2828,9410
30 Sep 1941,3496,6388,6560
30 Jun 1940,2116,1768,3050
31 Mar 1939,3475,8447,7730
31 Dec 1838,6045,5427,1760
30 Sep 1836,8235,1496,6670
30 Jun 1833,4454,3646,4360
31 Mar 1831,3024,1266,3720
31 Dec 1729,8944,1196,1880
30 Sep 1729,2643,6786,2070
30 Jun 1730,1653,6615,8330
31 Mar 1731,0524,0325,7370
31 Dec 1630,1303,9994,7744,159
30 Sep 1631,5845,8284,6443,693
30 Jun 1632,9427,5154,6483,386
31 Mar 1631,2327,2004,8670
31 Dec 1530,1856,9867,8782,265
30 Sep 1526,0864,9987,4991,869
30 Jun 1521,4692,8817,1281,400
31 Mar 1520,5792,8293,1591,216
31 Dec 1420,1672,7396,4701,223
30 Sep 1419,9062,6926,1841,208
30 Jun 1419,3032,5355,7811,236
31 Mar 1418,6422,3555,4981,164
31 Dec 1317,7702,1794,6891,072
30 Sep 1316,6102,0024,542999
30 Jun 1315,8091,8114,435822

Quality Earnings: APLLTD has high quality earnings.

Growing Profit Margin: APLLTD's current net profit margins (9.9%) are higher than last year (6.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: APLLTD's earnings have declined by 12.6% per year over the past 5 years.

Accelerating Growth: APLLTD's earnings growth over the past year (80.1%) exceeds its 5-year average (-12.6% per year).

Earnings vs Industry: APLLTD earnings growth over the past year (80.1%) exceeded the Pharmaceuticals industry 18%.


Return on Equity

High ROE: APLLTD's Return on Equity (12.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.